Potential therapeutic implications of next generation sequencing (NGS)-based molecular profiling in HR+/HER2-metastatic breast cancer (mBC)

被引：0
|
作者：
Avesani, Barbara
Giontella, Elena
Caldart, Alberto
De Noni, Alessandro
Muzzarelli, Alice
Borghesani, Giulia
Insolda, Jessica
Biondani, Pamela
Parolin, Veronica
Pellini, Francesca
Scarpa, Aldo
Nottegar, Alessia
Lawlor, Rita T.
Mafficini, Andrea
Paris, Ida
Minucci, Angelo
Pasciuto, Tina
Fabi, Alessandra
Fiorio, Elena
Milella, Michele
机构：
[1] Azienda Osped Univ Integrata Verona, Med Oncol, Verona, Italy
[2] Azienda Osped Univ Integrata Verona, Verona, Italy
[3] Azienda Osped Univ Integrata Verona, Sect Breast Surg, Verona, Italy
[4] Univ Verona, Sect Pathol, Dept Diagnost & Publ Hlth, Verona, Italy
[5] Hosp Trust Verona, Verona, Italy
[6] Univ Verona, Sect Pathol, Verona, Italy
[7] ARC NET, Verona, Italy
[8] Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy
[9] Univ Cattolica Sacro Cuore, Dept Unit Mol & Genom Diagnost, Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy
[10] Univ Cattolica Sacro Cuore, Policlin Agostino Gemelli, Rome, Italy
[11] IRCCS, Precis Med Senol, Fdn Policlin Univ Agostino Gemelli, Rome, Italy
[12] Univ Verona Hosp Trust, Dept Oncol, Verona, Italy
[13] Univ Verona, Sch Med, Sect Oncol, Verona, Italy
[14] Verona Univ Hosp Trust, Verona, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13079
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Cost of recurrence among patients with HR+/HER2-metastatic breast cancer.
    Engel-Nitz, Nicole M.
    Becker, Laura
    Gerdes, Randall
    Hao, Yanni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [12] FDA Approves Sacituzumab Govitecan for Pretreated HR+/HER2-Metastatic Breast Cancer
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2023, 29 (04): : SP315 - SP315
  • [13] Validation of Claims Algorithm to Identify HR+/HER2-Metastatic Breast Cancer Patients
    Chin, Andi
    Wu, Xiyuan
    Ip, Queeny
    Lyle, Derek
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 620 - 620
  • [14] Treatment sequencing of HR+/HER2-metastatic breast cancer (mBC) patients based on PIK3CA alteration status - A retrospective analysis of a US clinicogenomics database
    Turner, Stuart J.
    Wang, Iris
    Park, Jinhee
    Kanakamedala, Hemanth
    Lorenzo, Ines
    CANCER RESEARCH, 2020, 80 (04)
  • [15] Clinical outcomes among HR+/HER2-metastatic breast cancer patients with multiple metastatic sites
    Xie, J.
    Hao, Y.
    Li, N.
    Lin, P. L.
    Ohashi, E.
    Koo, V.
    Wu, E. Q.
    CANCER RESEARCH, 2016, 76
  • [16] Unmet need in heavily pre-treated patients with HR+/HER2-metastatic breast cancer (mBC) in the US: A ConcertAI analysis
    Waks, A. G.
    Gharaibeh, M.
    Sjekloca, N.
    Poluparthi, N.
    Shah, A.
    Bergamaco, E.
    MacCannell, T.
    Leung, G.
    Ntalla, I.
    Oko-osi, H.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S653 - S653
  • [17] A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2-metastatic breast cancer (MBC).
    Anders, Carey K.
    Le Rhun, Emilie
    Bachelot, Thomas Denis
    Yardley, Denise A.
    Awada, Ahmad
    Conte, Pier Franco
    Kabos, Peter
    Bear, Melissa
    Yang, Zhengyu
    Chen, Yanyun
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [18] Patient Preferences for HR+/HER2-Metastatic Breast Cancer Treatments in Italy: A Qualitative Assessment
    Arpino, Grazia
    De Angelis, Carmine
    Gerratana, Lorenzo
    Lambertini, Matteo
    Igidbashian, Sarah
    Bellini, Martina
    Giuntoli, Serena
    Guillaume, Xavier
    Behillil, Julie
    Graziani-Taugeron, Claire
    CANCER RESEARCH, 2024, 84 (09)
  • [19] Economic Burden of HR+/HER2-Metastatic Breast Cancer Among Adult Premenopausal Women
    Gauthier, Genevieve
    Gagnon-Sanschagrin, Patrick
    Guerin, Annie
    Burne, Rebecca
    Small, Tania
    Niravath, Polly
    Dalal, Anand A.
    ADVANCES IN THERAPY, 2018, 35 (04) : 503 - 514
  • [20] Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer
    Ban, Marija
    Mise, Branka Petric
    Majic, Ana
    Drazic, Ivanka
    Vrdoljak, Eduard
    FUTURE ONCOLOGY, 2018, 14 (06) : 537 - 544
12345